- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential “ - 100% Overall...
“ Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any...
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified...
SELLAS Announces Positive Data from the Phase 2a Study of SLS009 in r/r AML
- Update on the Phase 3 REGAL Clinical Trial of GPS in Acute Myeloid Leukemia (AML) - - Update on the Phase 2a Clinical Trial of SLS009 in relapsed/refractory AML, including topline data - NEW...
NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (SELLAS™™ or the Company), a late-stage clinical biopharmaceutical company focused on the development...
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering
SELLAS Announces Executive Leadership Reorganization
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data
SELLAS Life to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients